How does it work?

Enterogermina® 2 Billion comes in a convenient liquid vial format, which is easily administered to small infants and children as it is tasteless, odourless, and colourless.

Gastro-resistant

Bacillus clausii contained in Enterogermina® 2 Billion is resistant to gastric acid ensuring it survives digestive transit. This means that Enterogermina® is active where it needs to be, in the intestine. 2

Polyantibiotic-resistant

Bacillus clausii contained in Enterogermina® is resistant to most commonly used antibiotics because of the 4-strains included; O/C, SIN, N/R and T.

Intestinal flora

Each dose delivers billions of Bacillus clausii spores into the digestive tract where they work to restore intestinal flora, laying the foundation for symptom relief to occur. 1

Benefits of Enterogermina® 2 Billion

Helps maintain a healthy gut

Helps restore microbial flora

Helps protect against gut disturbances

Practical Info

1

Shake well

2

Snap the top to open

3

Swallow the contents

Dosage

Infants and Children (older than 1+ months)

1-2 vials per day in regular intervals as directed. This medication is for oral use only. Do not inject or administer in any other way. Shake the vial before use.

Adults (from 12 years)

2-3 vials per day as directed. This medication is for oral use only. Do not inject or administer in any other way. Shake the vial before use.

Frequently Asked Questions

Enterogermina works with the body to assist in restoring the natural balance in the gut. You probably have a few questions for us. Check out our FAQ and download a copy of our leaflet to keep.

Alternative leaflet download link
  • The effects of Enterogermina® can be seen within 1 to 3 days of starting use of the product.

    Enterogermina® can be taken during antibiotic therapy. During the course, and in the following 7 to 10 days, Enterogermina® 2 Billion is able to reduce the incidence of adverse events including abdominal pain and diarrhoea.1

  • If you are pregnant, may be pregnant, are planning to become pregnant, or are breastfeeding, talk to your doctor or pharmacist before taking this medicine. 1

  • Each pack of Enterogermina 2 Billion contains 20 vials, and each vial contains Bacillus clausii 2 billion spores.1

  • The Enterogermina® range is made in Italy. 1

  • If you are pregnant, may be pregnant, are planning to become pregnant, or are breastfeeding, talk to your doctor or pharmacist before taking this medicine. 1

  • Absolutely. Enterogermina is a gentle solution that won’t irritate the stomach. Similarly, taking Enterogermina® after a meal won’t inhibit the formula from getting where it needs to go. 1

  • The Enterogermina® range is best stored at room temperature (no higher than 25°C), and away from direct light and moisture. 1

  • The potential side effects of Enterogermina® are:

    Potential reactions of hypersensitivity either towards the components of the drug, or other closely related substances.

    Minor rashes, bacteraemia, septicaemia or sepsis in immuno-compromised patients or those hospitalised due to a serious illness.

    Urticaria as a result of allergic reaction. 1

    Should your general health worsen or if you experience any untoward effects while taking this medicine, please consult your healthcare provider for advice.

Browse Our Products

Enterogermina® assists in the prevention of intestinal disorders, maintains gut health, and balances the microbiota in adults and children. 1

VIEW ALL PRODUCTS

Stay Informed

Learn how different daily triggers could be contributing to intestinal disorders, and how a good probiotic could be the ally you didn't know tha tyou needed.

    * Nicholas Hall's CHC database, DB6, 2022

    1. Product information Enterogermina 2B
    2. Ghelardi E, et al. Survival and persistence of Bacillus clausii in the human gastrointestinal tract following oral administration as spore-based probiotic formulation. J Appl Microbiol. 2015;119(2):552-9.
    3. Abbrescia A, et al. Antibiotic Sensitivity of Bacillus clausii Strains in Commercial Preparation. Clinical Immunology, Endocrine & Metabolic Drugs 2014; 1:102-110